[1] Nabhan F, Dedhia PH, Ringel MD.Thyroid cancer, recent advances in diagnosis and therapy[J]. Int J Cancer, 2021, 149(5): 984-992. [2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. [3] Kim M, Kim BH.Current guidelines for management of medullary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2021, 36(3): 514-524. [4] Kim WG, Gong G, Kim EY, et al.Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental[J]. Clin Endocrinol (Oxf), 2010, 72(2): 256-263. [5] Fibbi B, Pinzani P, Salvianti F, et al.Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature[J]. Endocr Pathol, 2014, 25(3): 324-331. [6] Jaber T, Dadu R, Hu MI.Medullary thyroid carcinoma[J]. Curr Opin Endocrinol Diabetes Obes, 2021, 28(5): 540-546. [7] Thomas CM, Asa SL, Ezzat S, et al.Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5): 338-344. [8] Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. [9] Treglia G, Aktolun C, Chiti A, et al.The 2015 revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine[J]. Eur J Nucl Med Mol Imaging, 2016, 43(8): 1486-1490. [10] Wells SA, Jr., Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6): 567-610. [11] Maia AL, Siqueira DR, Kulcsar MA, et al.Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism[J]. Arq Bras Endocrinol Metabol, 2014, 58(7): 667-700. [12] Hu MI, Waguespack SG, Dosiou C, et al.Afirma genomic sequencing classifier and xpression atlas molecular findings in consecutive bethesda III-VI thyroid nodules[J]. J Clin Endocrinol Metab, 2021, 106(8): 2198-2207. [13] 沈雷, 曹慧敏, 李苑. 基于分子生物学的甲状腺癌诊疗进展[J]. 外科研究与新技术, 2015, 4(3): 196-200. [14] 中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, et al. 甲状腺结节和分化型甲状腺癌诊治指南[J]. 中华内分泌代谢杂志, 2012, 28(10): 779-797. [15] Li J, Chen Y, Wang X, et al.The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer[J]. Transl Cancer Res, 2021, 10(4): 1900-1906. [16] Yamaguchi K, Katagiri H, Takahashi M, et al.ProGRP is a possible tumor marker for patients with Ewing sarcoma[J]. Biomed Res, 2015, 36(4): 273-277. [17] Parra-Robert M, Orois A, Augé JM, et al.Utility of proGRP as a tumor marker in the medullary thyroid carcinoma[J]. Clin Chem Lab Med, 2017, 55(3): 441-446. [18] Ma SH, Liu QJ, Zhang YC, et al.Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma: Long-term follow-up[J]. Oncol Lett, 2011, 2(5): 975-980. [19] Fan W, Xiao C, Wu F.Analysis of risk factors for cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma[J]. J Int Med Res, 2018, 46(5): 1982-1989. [20] Machens A, Dralle H.Biomarker-based risk stratification for previously untreated medullary thyroid cancer[J]. J Clin Endocrinol Metab, 2010, 95(6): 2655-2663. [21] Jayasinghe R, Basnayake O, Jayarajah U, et al.Management of medullary carcinoma of the thyroid: a review[J]. J Int Med Res, 2022, 50(7): 1-20. [22] Pena I, Clayman GL, Grubbs EG, et al.Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer[J]. Head Neck, 2018, 40(1): 79-85. |